Medication Guides
Updated November 14, 2026

Vyvanse Shortage 2026: Why Brand Works When Generic Doesn't

Evan Brown
Written by Evan Brown · Prescription Savings Researcher
Published July 21, 2026 · Updated November 14, 2026
How we wrote this: we checked supply status against ASHP and drug shortage listings, and DEA quota figures against the Federal Register (including the November 10, 2026 notice). Takeda program details come from Takeda's pages. This is educational, not medical advice.
Quick answer

Yes, but unevenly. Generic lisdexamfetamine is still listed as a shortage (capsules and chewable tablets), mostly tied to active ingredient supply at individual manufacturers. Brand Vyvanse from Takeda has generally stayed available. On November 10, 2026 the DEA proposed a 2027 production quota of 62,832,521 grams for lisdexamfetamine, up from the 51,290,743 grams finalized for 2026. A higher ceiling helps eventually, but it doesn't fix any one manufacturer's ingredient problem, so there's still no confirmed end date.

The catch most patients hit: brand may be on the shelf, but your plan may refuse to cover it at anything near the generic price, because on paper the generic "exists." That gap is what this guide is really about.

What's new as of November 14, 2026

  • DEA proposed 2027 quota: 62,832,521 grams of lisdexamfetamine, published November 10. Public comments are due December 10, 2026.
  • Adderall quotas raised too. On November 4, the DEA adjusted its 2026 quotas for d,l-amphetamine and d-amphetamine (for sale) upward, effective immediately.
  • Chewable tablets are listed as short as well, not just capsules, per shortage trackers updated in early November.
  • Telehealth prescribing deadline: DEA's current telemedicine flexibilities for controlled substances end December 31, 2026, and a permanent rule has been under federal review since late August. If you get your prescription by telehealth, ask your prescriber now what changes in January.
  • Plan-choice season: Medicare open enrollment ends December 7, and HealthCare.gov enrollment runs through January 15. Check your 2027 plan's drug list for lisdexamfetamine before you commit.

Key takeaways

  • Brand and generic are having two different shortages. Takeda's supply has held; several generic manufacturers have struggled.
  • Quota increases don't fix individual supply problems. The DEA's quota is a national ceiling, not a delivery guarantee.
  • Insurers go by market-wide status, not your pharmacy's shelf, so brand often isn't covered at generic pricing.
  • Getting brand covered usually takes prescriber paperwork: shortage documentation, a formulary exception, or a prior authorization.
  • Partial fills are generally allowed for Schedule II drugs, so ask before leaving empty-handed.
  • Manufacturer copay card terms changed after generics arrived in 2023, so confirm current terms.

Patients on lisdexamfetamine have spent years watching Adderall headlines and assuming their medication was more stable. For a while it mostly was. Then generic lisdexamfetamine started slipping, and the pattern turned out to be strange: the brand-name version kept shipping normally while the generic, the one most patients and insurance plans steer people toward, became the hard one to find. The result is an unusual problem. The medication that's in stock is often the one your insurance won't pay for at a normal price.

1. Is Vyvanse really in shortage?

You have to split brand from generic, because they behave differently.

Generic lisdexamfetamine: ASHP lists lisdexamfetamine capsules as an active shortage, with its entry revised as recently as October 28, 2026. Drugs.com's shortage list, updated in early November, shows both capsules and chewable tablets. Manufacturers named in shortage listings over the past year include Amneal, Hikma, Solco, Mallinckrodt, and Elite, with Teva reporting limited 70 mg supply. Most cite an issue with the active ingredient. Statuses change often, and some makers have moved in and out of the list.

Brand Vyvanse (Takeda): brand supply has generally stayed available, and shortage listings are about generic products. That doesn't mean every pharmacy has every strength on the shelf every day, but Takeda's supply chain hasn't reported the active-ingredient disruption several generic makers have.

Practically, the first thing to learn is whether your pharmacy is out of one generic manufacturer's product or out of lisdexamfetamine entirely. Those are different problems with different fixes.

2. Why brand works when generic doesn't

This looks backwards, since brand drugs are usually the scarce ones and generics the reliable fallback. Lisdexamfetamine lost patent exclusivity in August 2023, and roughly a dozen generic manufacturers entered at once. Prescribing shifted quickly to generic because of lower copays, while overall demand kept climbing as adult ADHD diagnosis and treatment rose. Takeda kept making brand Vyvanse on its own established line. Several new generic entrants ran into active-ingredient sourcing problems specific to their facilities and suppliers.

Because lisdexamfetamine is a Schedule II controlled substance, production of the active ingredient is federally capped by DEA quota, on top of each company's own capacity. A generic maker with a sourcing problem can't just buy more raw material elsewhere. One company can be constrained while another has no issue at all, which is why availability varies so much from store to store. It usually comes down to which manufacturer a pharmacy's wholesaler stocks.

3. Timeline

Key dates in the lisdexamfetamine supply story
DateEvent
Aug 2023Lisdexamfetamine loses patent exclusivity; roughly a dozen generic manufacturers enter the market
Jun 2024CDC issues a Health Advisory on disrupted access to prescription stimulants
Jul 2024FDA tells DEA in writing that active ingredient shortage is behind shortages of generic lisdexamfetamine
Sep 2024DEA raises the 2024 lisdexamfetamine quota in response
Sep 2025DEA raises the lisdexamfetamine quota again, from about 32.7 to 39.9 million grams
Nov 2025DEA proposes a 2026 lisdexamfetamine quota of 42,057,460 grams
Jan 5, 2026DEA finalizes the 2026 quota at 51,290,743 grams, above its proposal
Nov 4, 2026DEA raises 2026 quotas for d,l-amphetamine and d-amphetamine (for sale) in an order effective immediately
Nov 10, 2026DEA publishes its proposed 2027 quotas, including 62,832,521 grams of lisdexamfetamine; comments due December 10
Nov 2026 (ongoing)Generic lisdexamfetamine capsules and chewable tablets remain on shortage lists; brand Vyvanse generally available

4. Which generic will your pharmacy have?

"The lisdexamfetamine shortage" is really a patchwork of individual manufacturer statuses, and those statuses shift month to month. A manufacturer listed as short in one snapshot may be listed as available in the next. Rather than trusting a static table, use these steps:

  • Ask your pharmacist which manufacturer they currently stock and whether they can order a different one.
  • Check ASHP's lisdexamfetamine entry for the latest manufacturer-by-manufacturer status.
  • Call independent pharmacies as well as chains. They often use different wholesalers and stock different generic makers.
  • Ask about a different strength combination if your prescriber agrees (for example, two capsules adding up to your dose), since individual strengths can go in and out of stock independently.

Practical tip: a pharmacy that's out of one maker's generic may still be able to order another's. Calling a second or third pharmacy often turns up a different manufacturer's product.

5. The DEA quota: what 62.8 million grams means

Because lisdexamfetamine is Schedule II, the DEA sets an annual aggregate production quota (APQ) that caps how much of the active ingredient all manufacturers combined may produce in the U.S. that year.

On November 10, 2026, the DEA published proposed 2027 quotas, including 62,832,521 grams of lisdexamfetamine. That compares with 51,290,743 grams finalized for 2026 and a 2026 proposal of 42,057,460 grams. Comments are due December 10, 2026, and the final 2027 numbers come only after the DEA reviews them. In the notice, the DEA says FDA expects domestic stimulant use to rise about 3.9% in 2027 and cites shortage concerns tied to telemedicine growth, supply chain problems, and manufacturing and quality issues.

A higher quota raises the legal ceiling. It doesn't fix a specific company's raw-material contract, packaging capacity, or quality-control backlog. That's the same gap that kept the Adderall shortage going after earlier quota increases, and it's why several lisdexamfetamine makers still report shortage status well after the ceiling went up. A significant share of the quota also supports exports, so the increase for U.S. patients is smaller than the headline number.

6. When will the shortage end?

No agency has published an end date for the generic shortage, and treating any projection as a plan is risky, since timelines for this drug class have slipped repeatedly since 2022. What would actually resolve it is each affected manufacturer fixing its own ingredient supply, independent of the quota. Some may recover in weeks; others haven't published a recovery estimate. Brand Vyvanse's steady supply doesn't speed generic recovery, because the operations are separate.

The realistic outlook is continued store-by-store inconsistency for generic lisdexamfetamine, with brand the more dependable option if your plan and budget allow. If your prescription depends on a manufacturer in shortage, ask your prescriber whether writing it so any manufacturer's product can be dispensed helps your pharmacist source it faster.

7. The insurance problem: why your plan won't cover brand

Most commercial and Medicare Part D formularies put brand-name drugs in a higher tier, or exclude them, once a generic exists. That rule turns on whether a generic exists nationally, not on whether it's in stock near you. A plan can be technically right that generic lisdexamfetamine is available while several pharmacies near you have none.

The practical result: a patient whose pharmacy is out of every generic may still face a high brand-tier copay or a denial, because as far as the insurer's system is concerned, nothing has changed.

How the workaround usually works

  • Shortage documentation from your prescriber. Some plans will process a temporary exception if your prescriber documents that generic was unavailable at your pharmacy or several nearby ones on specific dates.
  • Formulary exception request. A formal request that the plan cover a non-preferred or excluded drug at a lower tier for a documented access or clinical reason.
  • Prior authorization for brand. Some plans route brand requests through standard prior authorization. Ask which process yours uses.
  • Appeal if denied. A denial isn't final, and a dated record of the pharmacies you checked strengthens an appeal.

Our prior authorization and appeal guide walks through the process for major pharmacy benefit managers.

Open enrollment matters here. If you're choosing a 2027 plan, check how it treats lisdexamfetamine and brand Vyvanse: tiers, prior authorization, and quantity limits. Medicare open enrollment ends December 7. For HealthCare.gov plans, choose by December 15 for January 1 coverage; enrollment runs through January 15. Our guide to picking a Marketplace plan that covers your prescriptions shows how to check a drug against a plan.

8. Brand vs generic Vyvanse

Brand Vyvanse vs generic lisdexamfetamine, November 2026
FactorBrand Vyvanse (Takeda)Generic lisdexamfetamine
AvailabilityGenerally in stockInconsistent by manufacturer
Active ingredientLisdexamfetamine dimesylateSame (bioequivalent)
Typical cash priceHigher, often several hundred dollarsLower, and often much lower with a discount card
Typical insurance tierHigher tier or excluded once generic existsUsually preferred tier
Manufacturer supportHelp at Hand PAP; copay card terms vary, so confirmNo manufacturer PAP; use discount cards
Best whenGeneric is out everywhere and you can get an exception approvedYour usual manufacturer's product is in stock

Sticking with generic

  • Lower tier, and usually the cheaper cash option when in stock
  • A different manufacturer may have supply when your usual one doesn't
  • No exception paperwork if your plan already covers it

Switching to brand

  • May need prescriber and insurer paperwork to avoid a high cost
  • Cash price is much higher without a coupon or approved exception
  • Approval at generic pricing isn't guaranteed

9. If your pharmacy is out

1

Ask which manufacturer they're out of

"Out of lisdexamfetamine" and "out of the one manufacturer we usually carry" are different problems. Ask whether another maker's product can be ordered.

2

Call two or three other pharmacies first

Independents and different chains often stock different manufacturers. This also gives you a clearer picture and a record for any later insurer request.

3

Ask about a partial fill

Federal rules generally allow partial fills of Schedule II prescriptions as long as the total across fills doesn't exceed the amount prescribed. State rules and pharmacy policies also apply.

4

If no generic is available nearby, ask your prescriber about brand

Ask the office to document which pharmacies you checked and on what dates. That record is often what an exception or appeal needs.

5

Confirm coverage before you fill brand

Call your insurer or check your plan portal first, so you aren't surprised by a denial or a high cash price.

6

Plan ahead for December 31 if you use telehealth

DEA's temporary telemedicine flexibilities for controlled substances run through December 31, 2026. Ask your prescriber how your next prescription will be handled in 2027, and don't wait for your last fill to raise it.

7

Don't stop abruptly while you sort this out

CDC's 2024 advisory flagged the risks of disrupted stimulant access, including fatigue, mood changes, and turning to unregulated substitutes. Talk to your prescriber about a short bridge plan rather than going without.

10. Assistance and savings options

11. Eligibility and applications

Confirm current figures directly, since program terms change
ProgramWho it's forCovers
Takeda Help at HandUninsured or underinsured patients prescribed a Takeda medication; income proof requiredEligible Takeda brand products only
Discount cardsAnyone; no income requirementMost generics, including lisdexamfetamine
Medicare Extra HelpPart D enrollees with limited income and resourcesCovered Part D drugs on formulary
NeedyMeds / BenefitsCheckUpAnyone searching across many programsAggregates assistance and state or local resources
State pharmacy assistanceState residents who meet state rulesVaries by state

How applications generally work

  • Help at Hand: get the application from Takeda's site, include proof of income such as a recent tax return, and have your prescriber complete the clinical section. Takeda describes review as taking a few business days once complete, and approvals typically last up to a year before renewal.
  • Extra Help: apply through Social Security or your state Medicaid office with income and resource details for you and any spouse.
  • Discount cards: no application; use the card or app at checkout.

Medicare's Extra Help limits are updated yearly by CMS at Medicare.gov. Manufacturer thresholds aren't standardized, so confirm on each program's site.

12. Common mistakes that delay access

  • Assuming your insurer will switch you to brand without documentation.
  • Only calling pharmacies in one chain.
  • Waiting until the day you run out. Exceptions and applications take time, so start a week or more ahead.
  • Assuming an old coupon still applies.
  • Trying to stockpile a 90-day supply, which most plans and pharmacies won't allow for Schedule II drugs.
  • Not recording which pharmacies you checked and when.
  • Ignoring the December 31 telehealth change if that's how you're prescribed.

13. What should you do right now?

Is your usual pharmacy out of generic lisdexamfetamine?
No: fill as normal.
Yes: continue below.
Does another pharmacy or manufacturer have it nearby?
Yes: fill there, or ask your pharmacy to order that maker's product.
No: continue below.
Contact your prescriber about brand Vyvanse and start the insurance exception process

Ask the office to document the pharmacies and dates you checked, then contact your insurer about a formulary exception or prior authorization before filling brand. Don't ration doses or stop abruptly in the meantime.

Related: Adderall Shortage 2026: When Will It End, XR Status & What to Do Now. It covers the parallel Adderall shortage, including the DEA's November quota increases.

Frequently asked questions

It depends on the version. ASHP and drug shortage trackers list generic lisdexamfetamine capsules and chewable tablets as short, mostly tied to active ingredient supply. Brand Vyvanse from Takeda has generally stayed available. Which generic your pharmacy can get depends on its wholesaler and manufacturer, so stock varies a lot from store to store.

Takeda makes brand Vyvanse on its own established line. Generic lisdexamfetamine comes from roughly a dozen separate companies, and several have reported active ingredient problems at their own facilities or suppliers. One generic maker's problem doesn't affect Takeda or necessarily the other generic makers.

There is no confirmed end date. The DEA finalized a 2026 quota of 51,290,743 grams and, on November 10, 2026, proposed 62,832,521 grams for 2027. A higher quota raises the legal ceiling but doesn't fix each manufacturer's ingredient sourcing, so plan around your pharmacy's actual supply.

In a notice published November 10, 2026, the DEA proposed a 2027 aggregate production quota of 62,832,521 grams, with comments due December 10, 2026. That's above the 51,290,743 grams finalized for 2026. The final 2027 quota isn't set until the DEA reviews comments.

Not automatically. Many plans put brand Vyvanse in a higher tier or exclude it once a generic exists, whether or not the generic is on your pharmacy's shelf. Your prescriber may be able to request a formulary exception or prior authorization, documenting that generic was unavailable.

Often yes. Federal rules generally allow partial fills of Schedule II prescriptions as long as the total dispensed across fills doesn't exceed the amount prescribed. State rules and pharmacy policies also apply, so ask your pharmacist.

Generics must be bioequivalent to the brand, and most people notice no difference. Some report feeling different on a particular manufacturer's product, possibly because of inactive ingredients. If you notice a change, talk to your prescriber.

Generally no. Because lisdexamfetamine is a Schedule II drug, most plans and pharmacies limit fills to 30 days and don't allow early refills, even during a shortage. Ask your prescriber about a bridge plan instead.

Disclaimer: this guide is for general education and reflects publicly reported supply information and DEA filings as of November 14, 2026. It isn't medical advice. Supply, program terms, formulary rules, and federal prescribing rules can change quickly and vary by plan, region, and pharmacy. Confirm current availability and coverage with your pharmacy and insurer, and never change your stimulant medication, dose, or schedule without talking to your prescriber. If you can't obtain your medication and may run out, contact your prescriber or pharmacist right away.

Evan Brown
About the author
Evan Brown, Prescription Savings Researcher

Evan Brown researches prescription pricing and supply-chain mechanics and writes practical guidance for patients before they pay or run out.

View full profile →